在今年ASH年会上,我们也看到了大量的弥漫性大B细胞淋巴瘤(DLBCL)一线治疗领域的试验发表。2021年问鼎ASH年会最新突破性研究(LBA,Late-breaking Abstract)的POLARIX研究,为维泊妥珠单抗进入中国奠定坚实的循证基础,时隔3年,ASH年会上重磅...
6. 2024 ASH abstract 4415. https://ash.confex.com/ash/2024/webprogram/Paper202639.html. 7. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). B-Cell Lymphomas. Version 3.2024 8. 中国临床肿瘤学会指南工作委员...
If the presenting Author of an accepted abstract does not register by June 30, 2023, the abstract will be automatically withdrawn from the final program. If you decide to withdraw an abstract, please notify the Conference Organizers (abstract.ashno2023@gmail.com) by August 26, 2023. The 8th ...
The following topics are covered: common definitions, recommended program features, program goals, and the pharmacist’s role in the development of a comprehensive program. The recommendations in these guidelines represent a consensus of documented evidence, expert opinion, and professional judgment. They...
Abstract #2868, Session #614,Sunday, December 10from 6:00 - 8:00 p.m. PT Assessment of Outcomes of Consolidation Therapy By Number of Cycles of Blinatumomab Received in Newly Diagnosed Measurable Residual Disease Negative Patients with B-Lineage Acute Lymphoblastic Leukemia: In the ECOG...
Abstract The incidence, clinical characteristics, and prognostic factors of HIV-associated lymphoma remain poorly defined compared to HIV-negative lymphoma. Currently, there are no standard guidelines for treatment of these patients. We summarized several latest reports of HIV associated lymphoma from the...
These results include four-year overall survival (OS) data from the pivotal ZUMA-2 study and primary results from ZUMA-18, an expanded access study, evaluating the CAR T-cell therapy Tecartus in patients with R/R MCL that...
“We were astonished—we never expected these results,” Schetelig, the abstract’s senior author, said in a statement.3“Patients did not gain additional benefit from salvage chemotherapy at all. It suggests we should think about starting the process of allo-transplantation as soon as possible...
With the guidelines set, and bragging encouraged, the panel set off to discuss the most anticipated data from the recent ASH 2023. Matous on the Biggest Surprise to Come From ASH "I’m going to go old school here. I’m going to go with the abstract ...
The late-breaking abstract session will include the first presentation of results from the Phase 3 PERSEUS study evaluating a quadruplet regimen of DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) and doublet maintenance regime...